AstraZeneca's drug combo shows positive results in late-stage cancer trial

AstraZeneca (AZN.L) said on Friday a combination of its cancer drugs Imfinzi and Lynparza when added to platinum-based chemotherapy showed positive results in a late-stage trial in patients with advanced or recurrent endometrial cancer.